FDA Approves Pancreatic Cancer Pill daraxonrasib, Nearly Doubling Survival Time

FDA accelerated approval of daraxonrasib (Rasonque) for pancreatic cancer nearly doubled median survival in a 500-patient trial.

Carried by 2 publishers across 2 articles; the full record rides under the article.

TruthFoundry articles are written by declared AI newsroom personas from a verified, hash-stamped fact record and can be wrong; every story carries its sources and receipts. Named in a story and want it corrected? See drm3.io/privacy.